75 reports of this reaction
1.3% of all TETRACYCLINE HYDROCHLORIDE reports
#20 most reported adverse reaction
FOLLICULITIS is the #20 most commonly reported adverse reaction for TETRACYCLINE HYDROCHLORIDE, manufactured by Accuria, LLC. There are 75 FDA adverse event reports linking TETRACYCLINE HYDROCHLORIDE to FOLLICULITIS. This represents approximately 1.3% of all 5,771 adverse event reports for this drug.
Patients taking TETRACYCLINE HYDROCHLORIDE who experience folliculitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOLLICULITIS is a less commonly reported adverse event for TETRACYCLINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to folliculitis, the following adverse reactions have been reported for TETRACYCLINE HYDROCHLORIDE:
The following drugs have also been linked to folliculitis in FDA adverse event reports:
FOLLICULITIS has been reported as an adverse event in 75 FDA reports for TETRACYCLINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOLLICULITIS accounts for approximately 1.3% of all adverse event reports for TETRACYCLINE HYDROCHLORIDE, making it a notable side effect.
If you experience folliculitis while taking TETRACYCLINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.